ReviewFrontiers in pharmacology2022

Positive clinical outcomes following therapy with programmed cell death protein 1/programmed cell death ligand 1 inhibitors in neuroendocrine carcinoma of the cervix.

Rongyu Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.